Insider Transactions in Q1 2024 at Palisade Bio, Inc. (PALI)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 11
2024
|
John David Finley CEO, CFO, Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,558
+5.43%
|
-
|
|
Feb 09
2024
|
James R Neal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,920
+42.38%
|
-
|
|
Feb 08
2024
|
Stephanie Diaz Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,800
+40.63%
|
-
|
|
Feb 08
2024
|
Robert J. Trenschel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,920
+42.38%
|
-
|
|
Feb 08
2024
|
Cristina Csimma Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,800
+40.47%
|
-
|
|
Feb 06
2024
|
John David Finley CEO, CFO, Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,642
+3.57%
|
-
|
|
Feb 06
2024
|
Mitchell Lawrence Jones Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,153
-21.94%
|
$0
$0.44 P/Share
|
|
Feb 06
2024
|
Mitchell Lawrence Jones Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,891
+28.53%
|
-
|
|
Feb 06
2024
|
John David Finley CEO, CFO, Director |
BUY
Open market or private purchase
|
Direct |
10,000
+10.57%
|
$0
$0.47 P/Share
|
|
Jan 31
2024
|
Donald Allen Williams Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+25.0%
|
$0
$0.6 P/Share
|
|
Jan 31
2024
|
John David Finley CEO, CFO, Director |
BUY
Open market or private purchase
|
Direct |
10,000
+11.81%
|
$0
$0.56 P/Share
|
|
Jan 03
2024
|
John David Finley CEO, CFO, Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,309
+1.98%
|
-
|